RARE vs TVTX: stock comparison and AI forecast
Ultragenyx Pharmaceutical Inc. (RARE) and Travere Therapeutics, Inc. (TVTX) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
RARE Ultragenyx Pharmaceutical Inc.
- Price
- $15.43 -40.9% · 6M
- Market Cap
- $1.52B
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
TVTX Travere Therapeutics, Inc.
- Price
- $49.60 +16.3% · 6M
- Market Cap
- $4.44B
- P/E Ratio
- –
- Size
- mid-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Six-month price performance
Closing prices rebased to 100 at the start of the window.
Key facts
- TVTX is 2.9 times larger than RARE by market capitalization ($4.44B against $1.52B).
- Over the last six months TVTX returned +16.3% and RARE -40.9%.
- TVTX turns -18.7% of its revenue into net income, against -88.1% for RARE.
- Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | RARE | TVTX |
|---|---|---|
| Market Cap | $1.52B | $4.44B |
| P/B Ratio | – | 196.58x |
| EPS | $-5.18 | $-1.12 |
| Book Value/Share | – | $0.25 |
| Revenue/Share | $6.03 | $7.27 |
| FCF/Share | $-4.48 | – |
Profitability & Margins
| Metric | RARE | TVTX |
|---|---|---|
| ROE | – | -538.0% |
| ROA | -44.1% | -14.3% |
| ROIC | -58.6% | -20.9% |
| Gross Margin | – | 98.5% |
| Operating Margin | -78.6% | -20.5% |
| Net Margin | -88.1% | -18.7% |
| EBT Margin | -89.1% | -24.5% |
| Tax Rate | 1.2% | 3.3% |
Financial Health
| Metric | RARE | TVTX |
|---|---|---|
| Current Ratio | 1.40x | 3.00x |
| Quick Ratio | 1.25x | 2.80x |
| D/E Ratio | – | 36.56x |
| Financial Leverage | – | 37.56x |
| Interest Coverage | -32.5x | -3.7x |
| Working Capital | $155M | $423M |
Cash Flow
| Metric | RARE | TVTX |
|---|---|---|
| Operating Cash Flow | -$437M | $177M |
| Free Cash Flow | -$442M | – |
| Capital Spending | -$5M | – |
| FCF/Sales | -74.3% | – |
| CapEx/Sales | 0.8% | – |
Operational Efficiency
| Metric | RARE | TVTX |
|---|---|---|
| Asset Turnover | 0.50x | 0.77x |
| Receivables Turnover | 3.6x | 6.0x |
| Inventory Turnover | – | 0.2x |
| Fixed Assets Turnover | 2.6x | 239.0x |
| Days Sales Outstanding | 102 days | 60 days |
| Days Inventory | – | 1675 days |
| Payables Period | – | 584 days |
| Cash Conversion Cycle | – | 1151 days |
Income Statement
| Metric | RARE | TVTX |
|---|---|---|
| Total Revenue | $594M | $651M |
| Operating Income | -$467M | -$134M |
| Net Income | -$524M | -$122M |
| R&D Expense | $711M | $246M |
| SG&A Expense | $361M | $376M |
| Cost of Goods Sold | – | $10M |
Dividend & Shareholder Information
| Metric | RARE | TVTX |
|---|---|---|
| Shares Outstanding | 99M | 90M |
RARE vs TVTX: stock comparison and AI forecast
Which is bigger, RARE or TVTX?
TVTX is 2.9 times larger than RARE by market capitalization ($4.44B against $1.52B).
Which stock performed better over the last six months, RARE or TVTX?
Over the last six months TVTX returned +16.3% and RARE -40.9%.
Which one does Intratio's AI model rank higher, RARE or TVTX?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.